IVIRMA GLOBAL

What IVIRMA GLOBAL does

IVIRMA Global (legal entity EQUIPO IVI, S. L.; brand: IVI RMA Global) is a privately held reproductive medicine group headquartered in Valencia, Spain. Formed in 2017 through the merger of Spain-based IVI (founded 1990 by Professors José Remohí and Antonio Pellicer) and US-based Reproductive Medicine Associates (founded 1999), the group operates 200+ clinical offices and 95+ laboratories across 15 countries in Europe (Spain, Italy, Portugal, UK, Sweden, Denmark, Iceland, Czech Republic), North America (USA, Canada), Latin America (Brazil, Chile, Panama), and the Middle East. Patients travel from more than 180 countries to access services, with over 100 babies born daily and 180,000-plus treatments delivered in 2023 rising to a projected 200,000-plus in 2025.

The group delivers a full clinical-art stack of assisted reproduction services: artificial insemination, conventional in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), egg donation, fertility preservation via oocyte vitrification at -196°C, and a complete preimplantation and prenatal genetic testing menu (PGT-A, PGT-SR, PGT-M, Carrier Genetic Test, Sperm Aneuploidy Test, Non-Invasive Prenatal Test, Products of Conception analysis). Laboratory techniques are differentiated by time-lapse incubators that record embryo cell division in real time, MACS magnetic-activated sperm sorting, and extended embryo culture to the blastocyst stage. Multiple wholly-owned regional brands (RMA Network, Boston IVF, Conceptions, IVI Spain, IVI UK, IVI Italy, Ginemed, Ginefiv, Create Fertility, Genera, Livio, Carl Von Linne, TRIO Fertility, Ferticare, Art Fertility) preserve local market identity while consolidating under a unified parent. The IVI RMA Global Research Alliance operates 7 research centers across 15 research areas with 350-plus researchers and a publication portfolio of more than 3,000 scientific papers (reportedly double the rest of the industry combined).

The business model is direct-to-consumer healthcare services with quote-based per-treatment pricing that varies by procedure and geography. Revenue is generated from clinical ART services plus incremental genetic-testing add-ons performed across the owned clinic network. Distribution is exclusively through the owned clinic footprint; there is no third-party reseller or payer-channel distribution. The IVI RMA Global Education platform extends the model into training services (postgraduate university partnerships, 50+ online courses) targeting reproductive medicine professionals, while the biennial International IVI RMA Congress and annual US symposium establish scientific authority that funnels physician referrals. In 2025 the group reported 2.63% global market share of a $19.57B IVF services market — the largest single share in a market where the top 10 players collectively hold just 7.9%.

Name

IVIRMA GLOBAL

Legal name

EQUIPO IVI, S. L.

Website

https://ivirma.com

Company type

Private

Founded year

1990

Operating status

Operating

Short description

IVIRMA Global is the world's largest reproductive medicine group, operating 200+ clinical offices and 95+ labs across 15 countries to deliver IVF, ICSI, egg donation, fertility preservation, and preimplantation genetic testing services to patients from 180+ countries.

Ownership category

akta.pro rank

Product category

Reproductive Medicine Services

NAICS

Family Planning Centers (621410), Medical and Diagnostic Laboratories (62151)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Fertility, Reproductive Endocrinology & IVF Centers (HLAFAJAD)

akta.pro secondary industries

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC)

Keywords

• Assisted reproduction services
• Fertility treatments
• In vitro fertilization
• Preimplantation genetic testing
• Fertility preservation

Headquarters

HQ city

Valencia

HQ country

Spain

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Assisted Reproductive Treatment Services: Healthcare services revenue generated from providing fertility treatments including IVF, artificial insemination, egg donation, fertility preservation, and related clinical services to patients
2. Genetic Testing Services: Preimplantation genetic testing services (PGT-A, PGT-SR, PGT-M) and prenatal testing offered as part of treatment protocols

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

IVIRMA Global operates as the world's leading reproductive medicine group, delivering assisted reproductive treatments including In Vitro Fertilization (IVF), ICSI, artificial insemination, egg donation, and fertility preservation across 200+ clinical offices and 95+ labs in 15 countries. The group also provides comprehensive genetic testing services (PGT-A, PGT-SR, PGT-M, Carrier Genetic Test, Sperm Aneuploidy Test, NIPT, and Products of Conception analysis) and is supported by a research alliance and global education programs.

Product overview

IVI RMA Global is the world's leading reproductive medicine group offering a comprehensive portfolio of assisted reproductive services and technologies. The company operates as a unified platform with multiple regional sub-brands (including IVI, RMA Network, Boston IVF, Conceptions, Ginemed, Ginefiv, Art Fertility, Create Fertility, Genera, Livio, Trio Fertility, Ferticare, and IVI Latin America) across 200+ clinical offices in 15 countries. Core clinical services include artificial insemination, In Vitro Fertilization (IVF), egg donation, and fertility preservation. The company offers advanced laboratory techniques including Time-lapse incubators, ICSI, MACS sperm selection, and extended embryo culture to blastocyst stage. Genetic testing services span preconception (Carrier Genetic Test, Sperm Aneuploidy Test), preimplantation (PGT-A, PGT-SR, PGT-M), and prenatal phases (NIPT, Products of Conception). The organization is supported by the IVI RMA Global Research Alliance (7 research centers, 15 research areas, 150+ researchers) and IVI RMA Global Education (postgraduate programs with universities, 50+ online courses).

Differentiator

Problem solved

Functional benefit

Products and services

• In Vitro Fertilization (IVF) Laboratory procedure uniting ovum with sperm via conventional IVF or Intracytoplasmic Sperm Injection (ICSI) to obtain fertilized embryos for transfer; offered to women, men, and couples facing infertility.
• Artificial Insemination Deposition of a prepared semen sample inside the woman's uterus to increase sperm potential and improve fertilization chances; offered to individuals and couples seeking less invasive fertility treatment.
• Egg Donation Treatment in which a woman uses donor oocytes combined with sperm to produce embryos for transfer and achieve pregnancy; offered to patients who cannot use their own oocytes.
• Fertility Preservation Techniques including oocyte vitrification for preserving fertility in women who wish to postpone motherhood or who have been diagnosed with cancer; offered to women seeking to defer childbearing or facing medical treatments that may compromise fertility.
• Preimplantation Genetic Testing for Aneuploidies (PGT-A) Genetic test detecting numerical alterations in embryo chromosomes, identifying whether there are more or fewer than the normal 46 chromosomes; offered as part of IVF treatment protocols.
• Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR) Genetic test detecting structural rearrangements in embryo chromosomes that may cause infertility, repetitive miscarriages, or genetic disorders; offered within IVF cycles.
• Preimplantation Genetic Testing for Monogenic disorders (PGT-M) Genetic test detecting alterations or mutations of a particular gene that would cause monogenic or Mendelian disorders in embryos; offered to couples with known inherited disease risk.
• Carrier Genetic Test (CGT) Preconception test identifying mutations in an individual to detect recessive inheritance disorders and X-linked mutations before pregnancy; offered to prospective parents.
• Sperm Aneuploidy Test (SAT) Diagnostic test studying sperm chromosomes to detect abnormal chromosome numbers; offered to male patients, particularly those with recurrent pregnancy loss or failed IVF cycles.
• Non-Invasive Prenatal Test (NIPT) Non-invasive prenatal screening test analyzing common chromosomal abnormalities including Down Syndrome, Edwards Syndrome, and Patau Syndrome; offered to pregnant patients.
• Products of Conception (POC) Analysis Test analyzing fetal tissue of gestational loss to determine whether miscarriage resulted from chromosomal aneuploidy; offered to patients experiencing pregnancy loss.

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• Island Reproductive Services (IRS)coreStrategic or Co-development Partner · 10 December 2025MidCap Advisors served as exclusive financial advisor to Island Reproductive Services during its partnership with IVI RMA North America. This transaction marks IVI RMA's entry into the New York City fertility market, expanding its network and services through the integration of IRS.

Scale indicators13 records

Recent moves9 records

Expansion highlights6 records

Regional players

• Monash IVF Group: Monash IVF is a leading fertility clinic operator in Australia and Southeast Asia, offering the same core ART services as IVI RMA but concentrated in the APAC region, making it a regional rather than global peer.
• TFP (The Fertility Partnership): TFP is a leading UK and European fertility clinic group (part of FutureLife), offering IVF and genetic services directly comparable to IVI RMA's European operations and competing for the same international patient flow.
• Genea Limited: Genea is a major Australia-based fertility services and technology provider, comparable to IVI RMA in clinical offering but limited geographically, with a notable focus on ART lab technology development.

Direct peers

• Inception Fertility: Inception operates a large U.S. fertility clinic platform (including Prelude and Aspire Fertility), making it one of the closest direct competitors in the multi-clinic, multi-brand IVF services model that IVI RMA has pioneered.
• Shady Grove Fertility: Shady Grove Fertility is one of the largest U.S. fertility clinic networks, offering a comparable suite of ART services including IVF, donor egg, and PGT, and competing directly with IVI RMA's RMA Network and Boston IVF brands in the U.S. market.
• NewHope Fertility Center: NewHope Fertility is a U.S.-based fertility clinic group with a focus on natural-cycle and mild stimulation IVF, directly competing for U.S. patients in the same end market as IVI RMA's North American brands.
• CCRM Fertility: CCRM is a U.S.-based fertility clinic network offering IVF, genetic testing, and fertility preservation services with a strong R&D focus, directly comparable to IVI RMA's core service offering and clinic-network model.

Others

• Vitrolife: Vitrolife is a global supplier of media, consumables, and instruments for ART labs; it is a key supplier/enabler to the IVF clinic industry rather than a direct competitor, but operates in the same reproductive medicine value chain.

Emerging players

• Progyny: Progyny is a U.S. fertility benefits management company that routes employer-covered patients to clinic networks including IVI RMA's U.S. brands, making it a partial competitor and a key channel partner for the network.

Broad incumbents

• CooperSurgical (CooperCompanies): CooperSurgical is a large diversified medical device and fertility services business with a global ART product portfolio (micropipettes, media, devices) and a U.S. fertility clinic footprint, overlapping with IVI RMA across both supplies and clinical services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ivirmaglobal

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries26 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IVIRMA GLOBAL